Overexpression of FERM Domain Containing Kindlin 2 (FERMT2) in Fibroblasts Correlates with EMT and Immunosuppression in Gastric Cancer

Figure 1

Analysis of FEERMT2 expression and prognosis in pancancer. (a) FERMT2 expression in cancers in The Cancer Genome Atlas (TCGA) paired samples. The Kruskal-Wallis test was conducted. (b) FERMT2 expression in breast invasive carcinoma (BRCA), colon adenocarcinoma (COAD), kidney renal clear cell carcinoma (KIRC), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), skin cutaneous melanoma (SKCM), thyroid carcinoma (THCA), pancreatic adenocarcinoma (PAAD), and stomach adenocarcinoma (STAD) from the Human Protein Atlas (HPA) database. GEPIA2 tool was conducted to perform overall survival analyses of different tumors in TCGA by FERMT2 gene expression (c, d). The survival map and Kaplan-Meier curves with positive results are shown, and the optimal cut-off value to be used for sample grouping is derived from the “surv_cutpoint” function in the “survminer” package (d). Based on the TCGA data, the expression levels of the FERMT2 gene were analyzed by the main pathological parameters of (e) bladder urothelial carcinoma (BLCA), (f) head and neck cancer (HNSC), (g) KIRC, (h) kidney renal papillary cell carcinoma (KIRP), (i) mesothelioma (MESO), and (j) STAD. Log2 (TPM+1) was applied for log scale. , , and .

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)